
2nd International Expert Meeting on Gluten Sensitivity Munich, December 1st 2012

NON CELIAC GLUTEN SENSITIVITY IN ADULTS: CLINICAL AND SEROLOGICAL ASPECTS

Umberto Volta Coeliac Disease and Malabsorption Unit St.Orsola-Malpighi Hospital AIC Board Coordinator





Gwyneth Paltrow said she got rid of gluten to lose her extra "holiday" **and Lady Gaga** is the latest celebrity to embrace a **gluten-free diet.**



NCGS is still a debatable entity because of the difficulty of objectively demonstrating this diagnosis which remains highly presumptive



USA TODAY 2008

A market survey has evidenced that 15-25% of the U.S. population (i.e., from 40 to 70 milions) think that to eat gluten-free is a food regimen for staying healthy



The Washington Post 2011

The American press has hypothesized that 17 milions of U.S. citizens (i.e., 6% of the U.S. people) complain of gluten sensitivity although evidencebased data its on prevalence are lacking.

Gluten-free market is in a great expansion in U.S.



NCGS: an Internet problem or an emerging clinical entity?

Media hype

Scientific production

The ratio between Google and PubMed citations for NCGS is higher than 5000:1

The number of Internet citations is more than 10 times higher than that for breast cancer, Alzheimer disease and gastric cancer In the last 2 years papers on NCGS in IF journals are rapidly increasing

However, most of them are reviews or commentaries with only a few clinical studies on series of NCGS patients




THE FIRST DEMONSTRATION OF GLUTEN SENSITIVITY

Gluten-sensitive diarrhea without evidence of celiac disease Cooper BT, Holmes GKT et al Gastroenterology 1980

- Six of eight adult female patients suffering from abdominal pain and chronic diarrhea had dramatic relief on a GFD and return of symptoms after a double-blind cross-over challenge
- Previous attempts of treatment including a milk-free diet were ineffective
- Duodenal biopsy showed minor abnormalities (no villous atrophy)
- No immunological abnormalities were found in these subjects
- These 6 patients were diagnosed as having gluten-sensitive diarrhea without evidence of celiac disease



New Understanding in Gluten Sensitivity



Which is/are the toxic component/s?

gluten or wheat fractions (wheat amylase/trypsin inhibitor)

Unknown pathogenic mechanisms, including:

innate immunity, low-grade inflammation, starch carbohydrate malabsorption, etc..


Volta U, De Giorgio R, Nat Rev Gastroenterol Hepatol 2012




Non Celiac Gluten Sensitivity(NCGS): Bologna experience

- Seventy-eight patients (56 females e 22 males F/M = 2.5 : 1, median age 38 years, range 17-63) were diagnosed as having NCGS in the Coeliac Disease Unit of Bologna University between January 2009 and June 2011
- In all the 78 pts NCGS was suspected on the basis of intestinal and/or extraintestinal symptoms with an early onset (a few hours or days) after gluten ingestion. In all of them coeliac disease (CD) and wheat allergy were excluded by means of CD serology (EmA and tTGA), duodenal biopsy and and specific IgE/Prick tests to wheat.
- NCGS was confirmed by a trial of strict GFD for 6 months with a quick disappearance of symptoms, followed by an open gluten challenge of 1 month with an immediate relapse of the clinical picture
- All the 78 NCGS patients were tested for antibodies to gliadin of first (AGA) and second generation (DGP) as well as for HLA typing; total serum IgA were determined in order to exclude an IgA deficiency
- Antibody and genetic results obtained in the 78 NCGS patients were compared with those found in 80 CD patients






*The majority of patients displayed more than 2 symptoms



*The majority of patients displayed more than 2 symptoms



Serology in non celiac gluten sensitivity (NCGS) and in celiac disease (CD)






AGA IgG (cut-off 50 AU)




NCGS Pos. 44/78 (56%)


Celiac Disease Pos. 65/80 (81%)



Volta U et al., J Clin Gastroenterol 2012

AGA IgA (Cut-off 15 AU)





Volta U et al. J Clin Gastroenterol 2012


AGA prevalence in other diseases and healthy controls

- Connective tissue disorders 9%
- Irritable bowel syndrome (IBS) 20%
- Autoimmune liver diseases 21%
- Blood donors

2%

AGA IgG is not a marker neither specific nor highly sensitive for NCGS, but for the time being its positivity (especially at a high titer) in patients with suspected NCGS can contribute to this diagnosis

AGA IgG in Non Celiac Gluten Sensitivity (NCGS) before and after GFD




The duration of GFD was: < 6 months in 11 coeliacs; > 6 and < 12 months in 21 coeliacs, and > 12months in 14 coeliacs.





GENETICS (HLA typing)



Absence of correlation between NCGS and HLA-DQ2 and/or –DQ8



- A normal small bowel mucosa was observed in 58% of 78 NCGS patients studied (V/C ratio ≥3:1, IEL < 25%, normal villi, i.e. Marsh-Oberhűber type 0)
- In the remaining 42% of NCGS patients a slight IEL increase (between 25% and 40%) was observed (Marsh-Oberhűber type 1)
- No increase of γ/δ^+ T lymphocytes when determined

Clinical features of NonCeliac Gluten Sensitivity (NCGS)

- NCGS is rare in infancy being more frequent in adults and in females than in males.
- Symptoms related to gluten ingestion (previously absent) appear some months or years before the diagnosis.
- Frequent coexistence of other food intolerances, i.e. lactose and fructose intolerance.
- Differently from coeliac patients, subjects with NCGS usually lose weight after GFD.
- A subgroup of NCGS patients does not improve by consuming commercially available gluten-free products and needs naturally gluten free foods.
- It is not known if NCGS patients are at risk for associated autoimmunity and complications like coeliacs.
- NCGS is frequently observed in 1st degree relatives of coeliac disease patients.



Pierre Auguste Renoir, The two sisters 1881



Non Celiac Gluten Sensitivity and Coeliac Disease are like two sisters with similar features, but with substantial differences

It is not rare to find NCGS cases among first degree relatives of celiacs

About 12% of NCGS cases of our study were 1st degree relatives of celiacs

Volta U, JCG 2012





The aim of this project is to have a picture of NCGS in Italy through a questionnaire which will be employed to collect prospectively data of pts with suspected NCGS in Italian Centers for gluten-related disorders in the period September 1st 2012-February 28 2013.

The NCGS form will allow to collect data about:

1)symptoms and signs of clinical presentation 2)frequency and timing of symptoms 3)duration of symptoms before diagnosis 4)who was the first to think about it 5)associated disorders; 6) familiarity for coeliac disease (CD) and HLA typing 7) 1st and 2nd generation gliadin antibodies 8)duodenal biopsy (if performed).

Moreover, another relevant aim is to verify the ratio between NCGS/CD cases during the 6 months of the study.

Inclusion criteria: symptoms elicited by gluten ingestion Exclusion criteria: lack of correlation symptoms/gluten ingestion; tTG or EmA positivity.





Scientific Board for Non Celiac Gluten Sensitivity (NCGS) Coordinators: U. Volta, G.R. Corazza, E. Tosi (President AIC), O. Lovello (President F.C.) Members M.T. Bardella, A. Calabrò, G.R. Corazza, C. Corposanto, O. Lovello, C. Pilo, A. Pucci, E. Tosi, R. Troncone, U. Volta


Geographical distribution of the 493 Italian Centres for Coeliac Disease diagnosis invited to participate

	<mark>493</mark>	
abruzzo	14	trentino umbria veneto abruzzo alto adige calabria 0,2% 3,2% 2,8% 14/493 1,4% bachigesta 1,6% 16/493 20/493 16/493 16/493 8/493 campania
alto adige	7	toscana 0,2% 3,2% 4,0% 2,8% 14/493 1,4% 7/493 1,6% campania 4,3% 21/493 1/493 16/493 20/493 4,9% 24/493 4,9% 24/493
basilicata	4	4,3% 21/493
calabria	8	1,8% 9/493sardegna
campania	24	5,1% 25/493
emr	56	
fvg	10	emr 11,5% 56/493
lazio	18	puglia 4 5% 22/493
liguria	14	fvg 2,0% 10/493
lombardia	169	piemonte - vda lazio
marche	14	3,6% 18/493
molise	1	molise liguria 2,8% 14/493
piemonte - vda	40	0,2% 1/493
puglia	22	marche_
sardegna	25	2,8% 14/493 lombardia
sicilia	9	34,3% 168/493
toscana	21	
trentino	1	
umbria	16	
veneto	20	




CENTRES PARTICIPATING IN THE PROJECT BY THE END OF OCT. 2012

in 2 months only 40 centres out of the 493 invited (8%) agreed to participate. Up to the end of October 2012, 115 cases, median age 60 years, range 18-80 yrs, ratio F/M: 5.5:1, were enrolled.






GASTROINTESTINAL SYMPTOMS IN 115 NCGS CASES






EXTRAINTESTINAL SYMPTOMS IN 115 NCGS CASES






FREQUENCY OF SYMPTOMS AFTER GLUTEN INGESTION








TIMING OF SYMPTOM APPEARANCE AFTER GLUTEN INGESTION








DURATION OF SYMPTOMS BEFORE NCGS DIAGNOSIS








WHO WAS THE FIRST TO THINK ABOUT NCGS








ASSOCIATED DISORDERS IN NCGS PATIENTS






FAMILIARITY FOR CD AND HLA TYPING IN NCGS



16.5% of NCGS cases were 1st degree relatives of CD patients




1st and 2st GENERATION GLIADIN ANTIBODIES IN NCGS







INTESTINAL BIOPSY IN NCGS







PROSPECTIVE SURVEY IN PATIENTS WITH SUSPECTED NCGS

- Results of our survey on NCGS are still preliminary (only two months of data collection and with a too few number of participating centers) and do not allow to draw any conclusion
- The participation of a higher number of centers will allow to have a more complete picture of NCGS in Italy and to extrapolate some data about its hypothetical prevalence related to new diagnosed CD cases in the same period



